SB 203580 is a potent, selective pyridinyl imidazole inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway. Widely utilized in preclinical research, this compound acts as an… Read more
SB 203580 is a potent, selective pyridinyl imidazole inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway. Widely utilized in preclinical research, this compound acts as an ATP-competitive inhibitor to modulate cellular responses to stress, inflammation, and cytokine production. Laboratories employ SB 203580 as a chemical tool to investigate signaling mechanisms in areas such as oncology, stem cell biology, and autoimmune pathology. To support the rigorous demands of pharmaceutical development, this category includes high-quality reference standards, metabolites, and stable isotope labelled compounds. These specialized materials are essential for impurity profiling, method validation, and precise quantitative analysis, enabling researchers to maintain strict quality control throughout the testing and characterization of this inhibitor.